Key Developments: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,418.00GBp
22 Aug 2014
Price Change (% chg)

6.50p (+0.15%)
Prev Close
4,411.50p
Open
4,423.50p
Day's High
4,450.00p
Day's Low
4,398.00p
Volume
1,779,670
Avg. Vol
2,276,779
52-wk High
4,946.41p
52-wk Low
3,085.21p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Illumina, Inc announces strategic partnerships with AstraZeneca PLC, Janssen Biotech, Inc., and Sanofi SA to redefine companion diagnostics for oncology
Thursday, 21 Aug 2014 02:00am EDT 

Sanofi SA:Announces that Illumina, Inc has formed collaborative partnerships with AstraZeneca, Janssen Biotech, Inc., and Sanofi SA to develop a universal sequencing (NGS)-based oncology test system.Says the system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.  Full Article

Mitsubishi Tanabe Pharma Corp and AstraZeneca Plc announce research collaboration in diabetic nephropathy
Wednesday, 20 Aug 2014 02:07am EDT 

Mitsubishi Tanabe Pharma Corp and AstraZeneca Plc:Says a three-year research collaboration in the area of diabetic nephropathy.The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development.The collaboration will span from target selection up to the delivery of small molecule candidate drugs.The research will be performed in parallel at AstraZeneca's Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Mölndal, Sweden, and at MTPC's facilities in Japan.There is no financial commitment for the research involved and each party will contribute equal resource at their own cost.  Full Article

AstraZeneca Pfc announces positive top-line results from the phase III programme of CAZ-AVI in patients with complicated Intra-Abdominal Infections (cIAI)
Tuesday, 19 Aug 2014 02:01am EDT 

AstraZeneca Pfc:Announces positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections.CAZ-AVI met the objective of statistical non-inferiority compared to meropenem.The primary endpoint was a clinical cure rate 28 to 35 days after randomisation (the Test of Cure visit).CAZ-AVI also treated cIAI patients infected with ceftazidime-resistant bacteria as effectively as meropenem.The adverse event rate for CAZ-AVI in combination with metronidazole was similar to meropenem.  Full Article

AstraZeneca Pfc announces United States department of justice closes investigation into Plato clinical trial for Brilinta
Tuesday, 19 Aug 2014 02:01am EDT 

AstraZeneca Pfc:Says it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor).The government is not planning any further action.  Full Article

AstraZeneca PLC announces top-line results from phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients
Wednesday, 13 Aug 2014 02:00am EDT 

AstraZeneca PLC:Announces positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, pivotal Phase III clinical trials investigating potential of lesinurad, selective uric acid re-absorption inhibitor (SURI), as combination therapy for treatment of patients with symptomatic gout.Lesinurad is an investigational agent that inhibits URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid (sUA).CLEAR1 and CLEAR2 studied lesinurad (200mg and 400mg once daily) in combination with xanthine oxidase (XO) inhibitor allopurinol, in symptomatic gout patients not achieving target sUA levels on their current allopurinol dose.CRYSTAL studied lesinurad (200mg and 400mg once daily) in combination with the XO inhibitor febuxostat (80mg once daily) in gout patients with tophi.In CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met primary endpoint, with a statistically higher proportion of patients reaching target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone (p<0.0001).Three most commonly reported adverse events across the CLEAR1 and CLEAR2 trials for patients receiving lesinurad in combination with allopurinol were upper respiratory tract infection, nasopharyngitis and back pain.In CRYSTAL, the three most commonly reported adverse events for patients receiving lesinurad in combination with febuxostat were nasopharyngitis, arthralgia and upper respiratory tract infection.  Full Article

AstraZeneca PLC raises FY 2014 outlook - Conference Call
Thursday, 31 Jul 2014 07:00am EDT 

AstraZeneca PLC:Expects FY 2014 revenue to be in line with FY 2013 on a constant currency basis.Expects FY 2014 core EPS to decline in the low double digitsat CER.Reported revenue of $25.711 bln , EPS of $5.05 in FY 2013.FY 2014 revenue of $25.505 bln, EPS of $4.31 - Thomson Reuters I/B/E/S.  Full Article

AstraZeneca PLC Board recommends first interim dividend
Thursday, 31 Jul 2014 02:02am EDT 

AstraZeneca PLC:Board has recommended first interim dividend of $0.90 (53.1 pence, 6.20 Swedish crown).Amount of the dividend reflects the Board's aim of setting the first interim dividend at around a third of the prior year dividend, which last year was $2.80.Record date for first interim dividend payable on Sept. 15 is Aug. 15.Shares will trade ex-dividend from Aug. 13.  Full Article

AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study
Wednesday, 30 Jul 2014 02:07am EDT 

AstraZeneca PLC:Enters into clinical study collaboration with Kyowa Hakko Kirin for Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.Study will evaluate AstraZeneca's anti-PD-L1 antibody, MEDI4736, in combination with Kyowa Hakko Kirin's anti-CCR4 antibody, mogamulizumab, and AstraZeneca's anti-CTLA-4 antibody tremelimumab, in combination with mogamulizumab.MEDI4736, tremelimumab, and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which use the body's own immune system to help fight cancer.MEDI4736 and tremelimumab block the signals that help tumours avoid detection by the immune system, while mogamulizumab suppresses some of the immune cells that shield the tumour from the immune system.Under the terms of the agreement, AstraZeneca and Kyowa Hakko Kirin will co-fund the study, which will be conducted by Kyowa Hakko Kirin.Phase I part of the study is expected to establish a recommended dose regimen and Phase Ib will assess the safety and efficacy of the two combinations.Results from these studies will determine the future clinical development of the combinations.  Full Article

AstraZeneca PLC announces strategic respiratory transaction with Almirall
Wednesday, 30 Jul 2014 02:02am EDT 

AstraZeneca PLC:Says agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 mln on completion, and up to $1.22 bln in development, launch, and sales-related milestones.Says it will own the rights for the development and commercialisation of Almirall's existing respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational therapies.Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of devices, will also transfer to AstraZeneca.  Full Article

Qiagen NV and AstraZeneca collaborate to develop liquid biopsy-based companion diagnostic to advance EGFR Mutation Profiling in Lung Cancer Patients
Monday, 28 Jul 2014 02:00am EDT 

Qiagen NV and AstraZeneca:To collaborate for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer.Companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples.  Full Article

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

Search Stocks